The splicing specificity created by SNRPD3 and MYCN alongside the observed 100% survival in xenografted mice with depleted SNRPD3 expression suggests that neuroblastoma cancer cells are susceptible to therapeutic inhibition of SNRPD3. This evidence concerns the gene SNRPD3 and neuroblastoma.